[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-soft-tissue-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-soft-tissue-sarcoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100567947","biomarkers-of-resiliency-in-childhood-cancer-surgery-100567947",false,"NCT06674811","Biomarkers of Resiliency In Childhood Cancer Surgery","Digital Biomarker and Omics-Based Assessment of Surgical Resiliency in Children Undergoing Solid Tumor Resection: A Pilot Feasibility Study","BRICCS","Inclusion Criteria:\n\n* 3-25 years old at enrollment\n* With solid tumors of the chest, abdomen, and extremities including neuroblastic tumors, sarcoma including soft tissue and bone, kidney tumors, liver tumors, ovarian tumors, lung and pleural-based tumors, and intestinal tumors\n\n-OR-\n\n* Guardian or primary caregiver of patient 3-25 years old with one of the aforementioned tumors.\n\nExclusion Criteria:\n\n* Patients who are known to be pregnant or prisoners.","ALL","3 Years","25 Years",{"count":21,"type":22},40,"ESTIMATED","OBSERVATIONAL","This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery. The main questions it aims to answer are:\n\n1. Can information obtained from patients and their caregivers wearing smartwatches and answering questionnaires be used to measure how patients are recovering from surgery?\n2. Are there specific patterns in patients' circulating proteins and metabolites that are associated with stress after surgery?\n\nParticipants, including pediatric patients undergoing surgery for cancer and their primary caregiver, will be asked to:\n\n* wear a smartwatch\n* complete questionnaires\n* allow for extra blood to be drawn for this research study when they are having their regular blood draws for clinical purposes\n\nThese actions will occur at baseline prior to patients' surgery and then afterwards for up to one year. There are no changes to participants' clinical care or surgical care as a result of the study. Investigators will also collect participants' clinical information and cancer-specific outcomes. Participants will be remunerated for their time.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Pediatric Cancer","Neuroblastoma","Sarcoma","Wilms Tumor and Other Childhood Kidney Tumors","Childhood Soft Tissue Sarcoma","Childhood Bone Sarcoma","Childhood Malignant Intestinal Neoplasm","Childhood Malignant Liver Neoplasm","Childhood Malignant Lung Neoplasm","Childhood Malignant Ovarian Neoplasm","Childhood Malignant Pleural Neoplasm","Childhood Neuroblastic Tumor","Childhood Sarcoma",[40,41,42,43,44],"digital biomarker","remote monitoring","smartwatch","surgery","pediatric cancer","RECRUITING","2026-09-10",{"date":48,"type":49},"2026-09-14","ACTUAL",{"date":51,"type":49},"2025-01-15",{"date":53,"type":22},"2030-01-31",{"name":55,"class":56},"Mayo Clinic","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":57},"100610065","phase-1-hypofractionated-radiation-in-combination-with-b7-h3-car-t-cells-for-pediatric-patients-with-relapsedrefractory-sarcomas-100610065","NCT07222735","Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed\u002FRefractory Sarcomas","INCLUSION CRITERIA\n\n\\*a previously collected, autologous leukapheresis product can be used for T cell production\n\nCollection and manufacturing eligibility\n\n* Age ≤ 21 years old\n* B7-H3+ sarcoma; B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) using any previously obtained biopsy; a tumor is considered B7-H3 positive with a H score greater than or equal to 100\n\n  * Osteosarcoma\n  * Ewing Sarcoma\n  * Rhabdomyosarcoma Non-rhabdomyosarcoma soft tissue sarcomas\n* Evidence of relapsed (cancer that has completely responded \\[i.e., no evidence of disease using standard imaging modalities\\] to first-line therapy but has recurred for the first or subsequent time); or refractory (cancer that does not respond completely to treatment; cancer may be resistant at the beginning or may become resistant during treatment) disease after standard first-line therapy\n* Evaluable disease with presence of at least one lesion amenable to hypofractionated radiation therapy\n\n  * For dose expansion cohort: participants must also have additional evaluable disease beyond planned radiation field\n* Estimated life expectancy of \\> 12 weeks\n* Karnofsky or Lansky (age-dependent) performance score ≥ 60\n\n  * Participants with mobility limitations due to prior surgical intervention (i.e., amputation) but who are up in wheelchair or with other assistive devices will be considered ambulatory for the purpose of performance score determination\n* For females of child-bearing age:\n\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n  * Not lactating with intent to breastfeed\n* Participants must be eligible to undergo autologous apheresis or have an available previously collected autologous apheresis product\n\nTreatment eligibility\n\n* Age ≤ 21 years old at the time of manufacturing\n* B7-H3+ sarcoma\n* Evidence of relapsed or refractory disease after standard first-line therapy\n* Evaluable disease with the presence of at least one lesion amenable to hypofractionated radiation therapy\n\n  • For dose expansion cohort: participants must also have additional evaluable disease beyond the planned radiation field\n* Estimated life expectancy of \\> 8 weeks\n* Karnofsky or Lansky (age-dependent) performance score ≥ 60\n\n  • Participants with mobility limitations due to prior surgical intervention (i.e., amputation) but who are up in wheelchair or with other assistive device will be considered ambulatory for purpose of performance score determination.\n* Adequate cardiac function defined by echocardiogram with left ventricular ejection fraction ≥ 50%\n* Adequate renal function as defined by not exceeding the maximum serum creatinine listed below by age:\n\n  * 1 to \\\u003C2 years: 0.6\n  * 2 to \\\u003C6 years: 0.8\n  * 6 to \\\u003C10 years: 1\n  * 10 to \\\u003C13 years: 1.2\n  * 13 to \\\u003C16 years: male 1.5, female 1.4\n  * ≥ 16 years: male 1.7, female 1.4\n* Adequate pulmonary function defined as pulse oximetry ≥ 92% on room air\n* Total Bilirubin ≤3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age\n* Hemoglobin ≥ 7g\u002FdL (can be transfused)\n* Platelet count ≥ 50,000\u002FμL (can be transfused)\n* Absolute neutrophil count (ANC) ≥ 1000\u002FμL\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child-bearing age:\n\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n  * Not lactating with intent to breastfeed\n* If sexually active, agreement to use contraception until 3 months after T cell infusion\n\nEXCLUSION CRITERIA\n\nCollection and manufacturing eligibility\n\n* Known primary immunodeficiency\n* Known HIV positivity\n* Severe, uncontrolled intercurrent bacterial, viral, or fungal infection\n* Known active malignancy other than the B7-H3+ sarcoma being treated on study\n* Rapidly progressive disease (as assessed by the study PIs, with consideration for proximity to critical structures)\n* Presence of intracranial or spinal cord disease\n* Known underlying medical condition(s) for which, in the investigator's opinion, participation in this trial would not be in the best interest of the participant (e.g., compromises the health of the subject) or that could prevent, limit, or confound protocol assessments\n* Known severe hypersensitivity to corn starch or hydroxyethyl starch\n\nTreatment eligibility\n\n* Known primary immunodeficiency\n* Known HIV positivity\n* Severe, uncontrolled intercurrent bacterial, viral, or fungal infection\n* Known active malignancy other than the B7-H3+ sarcoma being treated on study\n* Receiving systemic steroid therapy exceeding the equivalent of 0.5 mg\u002Fkg\u002Fday of methylprednisolone, \\\u003C 7 days prior to CAR T cell infusion\n* Receiving systemic therapy \\\u003C 14 days prior to start of protocol therapy, which will interfere with the activity of the CAR product (in the opinion of the study PIs)\n* Received radiation therapy within the 4 weeks prior to start of protocol therapy\n* Rapidly progressive disease (as assessed by the study PIs, with consideration for proximity to critical structures)\n* Presence of intracranial or spinal cord disease\n* Known underlying medical condition(s) for which, in the investigator's opinion, participation in this trial would not be in the best interest of the participant (e.g., compromises the health of the subject) or that could prevent, limit, or confound protocol assessments\n* Known severe hypersensitivity to corn starch or hydroxyethyl starch","21 Years",{"count":66,"type":22},42,"INTERVENTIONAL",[69],"PHASE1","RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.\n\nPrimary objective:\n\n\\- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphodepleting chemotherapy in patients ≤ 21 years of age with relapsed\u002Frefractory B7-H3+ sarcomas.\n\nSecondary objectives:\n\n* To describe the antitumor activity of B7-H3-CAR T cells in combination with HFRT\n* To determine if B7-H3-CAR T cells traffic to tumor sites after combination treatment with HFRT",[28,72,73,30,74],"Childhood Osteosarcoma","Childhood Rhabdomyosarcoma","Ewing Sarcoma","2026-02-06",{"date":77,"type":49},"2026-02-09",{"date":79,"type":49},"2026-01-21",{"date":81,"type":22},"2031-11-05",{"name":83,"class":56},"St. Jude Children's Research Hospital"]